

16 **Abstract**<br>17 Background

18 Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system 19 and its changes are believed to be a significant contributor to inflammaging. Gonadal 20 hormones affect IgG glycome composition, suggesting that alterations in IgG glycosylation 21 might be one of the molecular mechanisms behind increased disease risk in perimenopause.

21 might be one of the molecular mechanisms behind increased disease risk in perimenopause.

22 Methods<br>23 LgG was isolated from 5,354 plasma samples collected from 1,940 females and 113 males at 24 multiple time points. IgG glycans were released, labelled with a fluorescent dye and 25 analysed by ultra-high-performance liquid chromatography. Mixed modelling was used to 26 determine average levels of individual IgG glycans in pre-menopausal women, menopausal 27 women, and men.

27 women, and men.

28 Findings<br>29 Large and statistically significant differences in IgG glycome composition were observed, 30 mainly reflecting decreased galactosylation and sialylation of glycans in menopausal 31 women. During perimenopause women had a significant higher rate of increase in 32 agalactosylated structures (0.051/yr;  $95\%$ CI = 0.043 - 0.059, p<0.001), and decrease in 33 digalactosylated  $(-0.043/\text{yr}; 95\%$ CI =  $-0.050 - -0.037$ , p<0.001), and monosialylated glycans  $(-0.043/\text{yr}; 95\%$ CI =  $-0.050 - -0.037$ , p<0.001), and monosialylated glycans 34  $0.029/yr$ ; 95%CI =  $-0.034 - 0.024$ , p<0.001), compared to premenopausal women.

 $\frac{347}{95}$  ,  $\frac{347}{95}$ 

36 Proinflammatory  $\lg G$  glycome and the resulting decrease in the ability of  $\lg G$  to suppress

- 37 Iow-grade chronic inflammation may be an important molecular mechanism mediating the 38 increased health risk in perimenopause. IgG glycome changes considerably during
- 
- 39 perimenopause and may aid the diagnosis of perimenopause. 39 perimenopause and may aid the diagnosis of perimenopause.
- 
- 40 Funding<br>41 Croatian National Centre of Excellence in Personalised Healthcare, ESI Funds grant for the
- 42 Centre of Competences in Molecular Diagnostics, the Wellcome Trust and the Medical
- 43 Research Council (MRC)/British Heart Foundation (BHF). 43 Research Council (MRC)/British Heart Foundation (BHF).
- 

45 **Introduction**<br>46 Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system <sup>1</sup>. 47 In addition to directly affecting the effector functions of IgG by promoting its binding to 48 In different Fc receptors  $^2$ , glycans attached to IgG have numerous other roles in the regulation 48 different Fc receptors <sup>-</sup>, glycans attached to IgG have numerous other roles in the regulation<br>49 of the immune system <sup>3,4</sup> Glycans are also imnortant mediators of the anti-inflammatory 49 of the immune system <sup>3,4</sup>. Glycans are also important mediators of the anti-inflammatory<br>50 activity of lgG <sup>5,6</sup> as well as the driving force for one of the molecular mechanisms underlying 50 activity of IgG <sup>5,6</sup> as well as the driving force for one of the molecular mechanisms underlying<br>51 immunosuppressive activity of intravenous IgG (IVIG) therapy used to treat a variety of 52 immunological disorders<sup>7</sup>. Changes in IgG glycosylation are also believed to be an important 52 immunological disorders '. Changes in IgG glycosylation are also believed to be an important .<br>53 contributor to aging at the molecular level through a process called inflammaging <sup>8</sup>. contributor to aging at the molecular level through a process called inflammaging <sup>8</sup> 53 .

54 IgG glycome composition is tightly regulated and, despite the absence of a direct genetic<br>55 template, is heritable to a significant extent  $9,10$ . Alternative glycosylation (the attachment of 56 different glycan structures to the same glycosylation site) is structurally and functionally 57 analogous to coding mutations, but instead of being defined by sequence variation in 58 individual genes, glycome composition is inherited as a complex trait encoded by multiple 59 in genes  $^{11}$ . Genome-wide association studies identified a network of over 30 genes that 60 associate with the IgG glycome composition  $12-14$ . One of the regulators of IgG glycosylation 61 are sex hormones, and the association between estradiol and the IgG glycome composition 62 was confirmed to be causal  $^{15}$ . Recent randomised placebo-controlled clinical study 63 demonstrated that the deprivation of gonadal hormones resulted in an increase of 64 biological age measured by IgG glycans, which was completely prevented by estradiol  $\frac{65}{26}$  supplementation <sup>16</sup>.

66 Large population studies revealed that IgG glycome composition changes with age and that 68 menopause  $17,18$ . However, the association between changes in the IgG glycome 69 composition and menopause has not yet been validated. Perimenopause is accompanied by 70 different symptoms and is very often misdiagnosed due to changing hormone levels and 71 symptom overlap with other conditions. Menopause associates with an increased risk of 72 developing a range of diseases affecting metabolism, bones, cardiovascular system, brain, The conservation of the sease of the discussion of the disease affection, and the cardiovascular system, brain,<br>19. Leven cancer <sup>19</sup>. Early perimenopause diagnosis would enable timely interventions to ease For the cancer of the permitted and the model enable timely interventions to ease<br>74 . The symptoms decrease risks of developing accompanying diseases and timely monitoring of any changes in women's health status due to hormonal changes. To fill this knowledge<br>76 and explore the association of lgG glycome changes with perimenonalise we analysed 76 gap and explore the association of IgG glycome changes with perimenopause, we analysed<br>77 LigG N-glycome composition in 5,080 samples from 1,940 females in multiple time points 78 during their transition from pre-menopause to menopause, along with 274 samples from 79 113 males as an additional control. 79 113 males as an additional control.

80<br>81

## 82 **Methods**<br>83 Study population

84 Study subjects were individuals enrolled in the TwinsUK registry, a national register of adult 85 twins recruited as volunteers without selecting for any particular disease or traits  $^{20}$ . Data on 86 menopause was gathered through the multiple choice questionare asking women at each 87 visit: "What is your menopausal status?" with possible answers "Pre menopausal", "Going 88 through the menopause", "Post menopausal" and "Don't know" and "How old were you 89 when you became post-menopausal (when you stopped having periods for one year or 90 more)?". Consequently sample was defined as menopausal if questionar resulted with 91 "Post-menopausal" answer or age larger then reported age of becoming postmenopausal. 92 Similarly sample was defined as premenopausal if questionare resulted with "Pre 93 menopausa" answer of age at sampleing was less then reported age of becoming 94 postmenopausal reduced by 1 year. Any inconsistent (i.e. "Pre menopausal" answer at age 95 after becoming menopausal) or unreliable data (i.e. answered as "Going through the 96 menopause") were dropped from the study (Supplementary Table 1). The TwinsUK study 97 was approved by NRES Committee London-Westminster, and all twins provided informed 98 written consent. 98 written consent.

# 99<br>100

100 Isolation of IgG<br>101 IgG isolation from serum samples was performed on protein G monolithic 96-well plates as 102 previously described  $^{21}$ . In brief, 100  $\mu$ L of serum was diluted 1:7 (v/v) with PBS (phosphate 103 buffer saline) followed by filtration on a 0.45 µm GHP filter plate (Pall Corporation, USA). 104 Diluted and filtered serum samples were then transferred to the protein G monolithic plate, 105 which was then washed. Elution of IgG was performed with 1 mL of 0.1 mol/L formic acid 106 (Merck, Germany) followed by immediate neutralization of the mixture with ammonium 107 bicarbonate (Acros Organics, USA) to pH 7.0. IgG-containing eluate was aliquoted into PCR 108 plate (average mass of 15  $\mu$ g of IgG per sample) and dried in a vacuum centrifuge. 108 plate (average mass of 15 µg of IgG per sample) and dried in a vacuum centrifuge.

109<br>110

110 Deglycosylation, labelling and purification of IgG N-glycans<br>111 Deglycosylation, RapiFluor-MS labelling and purification of IgG N-glycans were performed 112 using the GlycoWorks RapiFluor-MS N-Glycan Kit obtained from Waters Corporation (USA). 113 The entire procedure was done following Waters' protocol (Waters Corporation 2017, 114 https://www.waters.com/webassets/cms/support/docs/715004793en.pdf). In the end, the 115 samples of released and labelled IgG glycans were stored at -20  $^{\circ}$ C until further use. 116 samples of released and labelled igc glycans were stored at  $\sim$  0 °C until function  $\sim$ 

116<br>117

117 HILIC-UHPLC-FLR analysis of RapiFlour-MS labelled IgG N-glycans<br>118 RapiFluor-MS labelled IgG N-glycans were analysed using ultra-high-performance liquid 119 chromatography based on hydrophilic interactions with fluorescence detection (HILIC-120 UHPLC-FLR) on Waters Acquity UPLC H-class instruments. The instruments were controlled 121 and monitored with the Empower 3 software, build 3471 (Waters, USA). Chromatographic 122 separation of glycan structures was performed on Waters UPLC Glycan bridged ethylene 123 hybrid (BEH) Amide chromatographic columns (130  $\AA$ , 1.7 µm BEH particles, 2.1x100 mm). 124 Solvent A was 50 mmol/L ammonium formate, pH 4.4, while solvent B was 100% LC-MS 125 grade acetonitrile. A linear gradient of 75-61.5 % acetonitrile (v/v) was used at a flow rate 126 of 0.4 mL/min over 30 minutes in a 42-minute analytical run. Each chromatogram was 127 separated into 22 glycan peaks containing IgG glycan structures (Supplementary Figure 1.).  $127$  separated into 22 givent peaks containing igo glycan structures (supplementary Figure 1.),<br>128 by automated integration <sup>22</sup> resulting in relative quantification of lgG N-glycans (total area 128 by automated integration <sup>22</sup> resulting in relative quantification of IgG N-glycans (total area

130 al.  $^{23}$  are presented in **Supplementary Table 2**. Formulas used for the calculation of IgG<br>131 derived traits are presented in **Supplementary Table 3** 131 derived traits are presented in Supplementary Table 3.<br>132

### 132

133 Statistical analysis<br>134 After UHPLC analysis, each measured glycan peak was normalized by total chromatogram 135 area. Observed relative glycan abundances were log transformed and batch corrected using 136 ComBat method (R package 'sva'  $^{24}$ ). After batch correction, values were back-transformed 136 ComBat method (R package 'sva' '<sup>-</sup>'). After batch correction, values were back-transformed<br>137 to relative abundance and derived traits were calculated according to **Supplementary Table** 137 to relative abundance and derived traits were calculated according to Supplementary Table<br>138 **3.** 138 **3.**<br>138 - 2

139 Overlapping measured N-glycomes and information available on menopause found in<br>140 TwinsUK register, resulted in 5354 samples from 1940 females and 113 males.

141 For each glycan trait the effect of menopause on the abundance was estimated by mixed 142 modelling (R package 'lme4'  $^{25}$ ). Logit transformed relative abundance was used as 143 dependent variable and sex, menopausal status (nested within sex), age and age-144 menopausal status interaction as fixed factors, as well as family ID and individual ID (nested 145 within family ID) as random intercepts and age as random slope. Using model, mean values 146 were estimated for each group and pairwise compared using t-test (post-hoc) (R package 147 (emmeans'  $^{26}$ ). Given multiple testing for large number of glycans, the control of false 148 discovery rate (FDR) was done by adjusting p values according to Benjamini-Hochberg's 148 discovery rate (FDR) was done by adjusting p values according to Benjamini-Hochberg's 149 method.<br>150 For the analysis of the rate of change of glycan abundances, average yearly changes were

151 calculated from two timepoints according to the formula: rate = (logit(glycan<sub>2</sub>) -152 logit(glycan<sub>1</sub>))/(age<sub>2</sub> – age<sub>1</sub>), where glycan is relative abundance resulted from normalized 153 chromatogram, and age is represented in years, assuming age<sub>2</sub> > age<sub>1</sub>. Depending on 154 menopausal status in the first and second timepoint measurements were classified into 155 three categories: premenopausal (both timepoints before menopause), perimenopausal 156 (first time point before, and second in the menopause), and menopausal (both time points in 157 menopause). Mean rates were estimated by the mixed model, in which rate was dependent 158 variable, and sex, menopausal group (nested within menopausal status) and mean age 159 (calculated as  $(age_2 + age_1)/2)$  were set as fixed factors, as well as family ID and individual ID 160 (nested within family ID) as random intercepts. Estimated mean rates for each menopausal 161 group and males were pairwise compared using t-test (post-hoc). FDR control was done by 162 adjusting p values according to Benjamini-Hochberg's method.

163 N-glycome (observed in one timepoint) potential for diagnosis of perimenopause was 164 analysed in a subset of women aged between 45 and 55 years by logistic regression with L1 165 regularization technique (R package 'caret' and 'glmnet'  $27,28$ ). The subset was split into 166 training (randomly chosen one measurement per family) and test (everything else) subset. 167 The logistic model was defined with menopausal status (TRUE/FALSE) as the dependent 168 variable, and age and all directly measured glycans as independent variables. To avoid 169 overfitting, coefficients of the logistic model were estimated by 10-fold cross validation on 170 training subset data, with hyperparameter lambda set to lambda<sub>min</sub>. The model was tested 171 on test subset; results are presented by receiver operating characteristic (ROC) curve. In 172 parallel, the null model was fitted in the same way but using only age as a predictor. 173 Observed ROC curves of the two models were compared by a bootstrap test (B = 2000) (R 174 package 'pROC'  $^{29}$ ).

175 The rate of N-glycome change (based on two timepoints) potential for diagnosis of<br>176 perimenopause was analysed in a subset of women with median two-timepoint age 177 between 45 and 55 years in the same way as diagnosis of menopause with IgG glycome 178 analysed in one timepoint. The perimenopausal category was defined as TRUE, while others 178 analysed in the timepoint. The periment parameter gray masses in the perimenopal category with others.<br>179 and foreign the period of the period of the period as TRUE, while other while other while the period of th 179  $\mu$ menopausal and premenopausal) were defined as FALSE. All statistical analyses were done. 180  $\mu$  using R  $^{30}$ .<br>181

- 
- 182
- 182

184 Results<br>185 LgG glycome composition was analysed in multiple samples from 1,940 females and 113 186 males from the UK registry of adult twins. The 1,087 samples from 732 individual twins (500 187 families) were collected prior to the onset of menopause, while 3,993 samples from 1,678 188 individual twins (969 families) were collected after the onset of menopause (Supplementary 189 Table 1). Additionally, IgG glycome was analysed in 113 men (274 samples) as an additional 190 control. A representative chromatogram with detailed structures of individual IgG glycans is 191 shown in Supplementary Figure 1. Mixed modelling was used to determine average levels of 192 individual IgG glycans in pre-menopausal women, menopausal women, and men. Large and 193 statistically significant differences were observed in multiple glycans, mainly reflecting 194 decreased galactosylation and sialylation of glycans in menopausal women (Figure 1). Levels 195 of individual IgG glycans are available in Supplementary Figure 2. 196 of individual individual in Supplementary Figure 2. Supplementary  $\frac{1}{2}$ 



197

198 Figure 1. IgG glycome composition in premenopausal women, menopausal women, and<br>199 men. Mean glycan abundances (% of total IgG glycome) and corresponding 95% confidence 200 intervals were estimated from fitted mixed model with logit transformed glycan as 201 dependent variable and sex, menopausal status (nested within sex), age and age-202 menopausal status interaction as fixed factors, as well as family ID and individual ID (nested 203 within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p 204 values less than 0.1 are shown. B - bisecting N-acetylglucosamine (GlcNAc), CF - core fucose, 205 GO - agalactosylated glycans, G1 - monogalactosylated glycans, G2 - digalactosylated 206 glycans, S1 - monosialylated glycans, and S2 - disialylated glycans. 206 glycans, S1 - monosialylated glycans, and S2 - disialylated glycans.

208 It is known that IgG galactosylation and sialylation decrease with age  $^{17}$  thus we attempted<br>209 to evaluate whether the changes in glycans associated with the transition to menopause 210 were more extensive than the age-related changes. Since we had multiple samples from the 211 same individual, we were able to calculate the rate of change of individual IgG glycans 212 through time. A subset of women in our cohort ( $n = 379$ ) entered menopause between two 213 sampling time points, thus for them, we were also able to calculate the rate of changes in 214 individual IgG glycans during the perimenopausal period. The comparison of the rate of age-215 related IgG glycome changes (when there was no change of the menopause status) with the 216 rate of IgG glycome changes during perimenopause (i.e., between time points when the 217 transition to menopause occurred) revealed statistically significant differences for a number 218 of glycans (Supplementary Figure 3). The most prominent differences in the perimenopause 219 period were the significantly larger rates of increase in the agalactosylated structures (G0) 220 and the decrease of digalactosylated (G2) and monosialylated (S1) glycans (Figure 2). During 221 perimenopause women had a significant higher rate of increase in agalactosylated 222 structures  $(0.051/\gamma r; 95\% CI = 0.043 - 0.059, p<0.001)$ , and decrease in digalactosylated  $($ 223 0.043/yr;  $95\%$ CI = -0.050 - -0.037, p<0.001), and monosialylated glycans (-0.029/yr;  $95\%$ CI =  $224$   $-0.034 - 0.024$ , p<0.001), compared to premenopausal women.



226

227 Figure 2. Average yearly change of IgG glycans in females during the perimenopause period,<br>228 Females in pre- or post-menopause, and males. Mean yearly change in IgG glycan 229 abundances and corresponding 95% confidence intervals were estimated from fitted mixed 230 model with logit transformed glycan as dependent variable and sex, menopausal status 231 (nested within sex), age and age-menopausal status interaction as fixed factors, as well as  $231$  (nested with sex), and agencies interaction agencies interaction as fixed factors, as  $\frac{1}{2}$ 

232 family ID and individual ID (nested within family ID) as random intercepts and age as<br>233 Frandom slope. Only adjusted post-hoc p values less then 0.1 are shown. B - bisecting 232 234 GlcNAc, CF - core fucose, GO - agalactosylated glycans, G1 - monogalactosylated glycans, G2 235 - digalactosylated glycans, S1 - monosialylated glycans, and S2 - disialylated glycans,

236 - Using single-point measurements of IgG N-glycans we attempted to predict menopause 237 status. The lasso model was fitted with menopausal status (TRUE for those who entered 238 menopause and FALSE for all others) as dependent variable and age and all directly 239 measured IgG glycans as predictors. The model was fitted on a randomly chosen one twin 240 per family (training set) in the subset of women with a two-timepoint median age between 241 45 and 55 years. The remaining twins were used for testing the fitted model. The same train 242 and test subset model with only mean age as a predictor were used to fit and test the model 243 for comparison (Figure 3A). IgG N-glycome in combination with age measured in a single 244 timepoint has shown a good classification performance, with the AUC of 0.853 (95% CI 245 0.823-0.880) outperforming only age as a predictor of perimenopause (AUC of 0.818, 95% CI 245 0.823-0.880) outperforming only age as a predictor of perimenopause (AUC of 0.818, 95% CI 246 0.783-0.849).<br>247 Since changes in the IgG glycome composition were the most prominent in te period of

248 perimenopause, we used the rate of changes in glycans to predict whether a given women 249 already entered the period of perimenopause, or not Figure 3B). The model was fitted on a 250 alreadomly chosen one twin per family (training set) in the subset of women with a two-251 timepoint median age between 45 and 55 years. The remaining twins were used for testing 252 the fitted model. The addition of the information about changes in the IgG glycan levels to a 253 prediction model notably increases AUC value compared to using only age (0.694, 95% CI 254 0.637-0.751 compared to 0.507, 95% CI 0.443-0.570, respectively). 254 0.637-0.751 compared to 0.507, 95% CI 0.443-0.570, respectively).

- 
- 255



- 257<br>258
- 
- 258

259 260 Figure 3. . Receiver operating characteristic (ROC) curves for the prediction of<br>261 perimenopause using IgG glycans measured in a single time point (A) and the change in IgG

- 262 glycan levels between the two timepoints (B). Graphs are showing area under the curve
- 263 (AUC) values with 95% confidence intervals. 263 (AUC) values with 95% confidence intervals.

## 264<br>265

265 **Discussion**<br>266 In this study we have shown the association between the period of perimenopause and the 267 extensive changes in the IgG glycome composition. Aging continuously associates with the 268 transition of the IgG glycome from an inflammation-suppressive to a proinflammatory 269 composition, but this change is much faster in the period when women are progressing 270 from a regular cycle to menopause. The depletion of estrogen during perimenopause and 271 menopause is an important event of aging since low hormone levels increase vulnerability 272 to diseases in hormone-responsive tissues, including the brain, bone, and the cardiovascular 273 system. Menopause is therefore more complex than just being a natural condition resulting 274 in symptoms; it needs to be considered as a long-term hormone deficiency leading to health 275 risks if not appropriately managed with lifestyle adjustments or hormone replacement 276 therapy (HRT)  $31$ . After entering menopause, there is an increased risk of developing obesity 277 and metabolic disease, cardiovascular diseases, osteoporosis and arthritis, dementia and 278 cognitive decline, and cancer <sup>19</sup>.<br>278 . cardiovascular diseases and arthritis, demonstration and arthritis, demonstration and arthritis, demonstration

279 Previous population studies revealed that IgG N-glycome composition changes with age,<br>280 especially in females in the time preceding the average age of menopause  $^{17,18}$ . In this study 281 we used multiple samples from the same individuals to confirm the association between 282 perimenopause and the extensive changes in the IgG glycome composition. The most 283 extensive change in the IgG glycome during perimenopause was a decrease in 284 extensive galactosylation and sialylation, a change that is generally associated with aging  $^1$ . Aging 285 continuously associates with the transition of the IgG N-glycome from an inflammation-286 suppressive to a proinflammatory composition, but this change is much faster in the period 287 when women are progressing from a regular cycle to menopause.

288 The age-related gradual decrease in the level of galactosylated IgG and the build-up of 289 agalactosylated IgG is known to exacerbate low-grade chronic inflammation  $32-34$  and acts as 290 an effector of pro-inflammatory pathological changes  $35,36$ . Decreased levels of IgG 291 galactosylation and/or sialylation have been associated with a wide range of autoimmune 292 conditions, such as systemic lupus erythematosus, inflammatory bowel disease, and many 293 others. Changes in these IgG glycosylation traits are also associated with disease 294 progression, disease activity, symptom severity, and response to treatment. In many cases, 295 these changes occur before the onset of symptoms  $\frac{37}{2}$ .

296<br>297

297 The rate of change from "young" to "old" IgG glycome increased significantly in the<br>298 perimenopausal period, suggesting that the loss of immunosuppressive functions of IgG may 299 be an underlying molecular mediator of at least some health risks in this period. The results 300 of this study also indicate the potential of the IgG glycome composition as a biomarker for 301 perimenopause. Perimenopause can last up to 15 years and is difficult to diagnose due to 302 bighly irregular hormonal cycles  $38$ . As a result of poor awareness and inappropriate use of 303 hormonal tests, women are often misdiagnosed with conditions such as fibromyalgia, 304 migraines, depression, or chronic fatigue syndrome and are frequently prescribed 305 antidepressants despite there being no evidence to support their use to improve the low and the being present the process of the low the low the low their there is imported the low the low to support the<br>305 . In the improved the low the low the low the low the low that early use of HRT leads.  $\overline{308}$  to a greater reduction of future disease incidence as well as minimising the duration of 308 to a greater reduction of future disease incidence as well as minimising the duration of 309 symptoms<sup>40</sup>.

### 310

310 311 Recent placebo-controlled randomised trials indicated the importance of estrogens in the 312 regulation of IgG glycosylation  $^{15,41}$ , thus it seems quite probable that the decrease in 313 estrogen levels is an important driver of changes in IgG glycosylation in primenopause. 314 Contrary to estrogens that have a very short half-life in circulation, IgG has a half-life of 315 three weeks<sup>42</sup>, which implies that the current composition of the IgG glycome is affected by  $1316$  average concentrations of estrogen in the past 3-4 weeks. Since changes in the IgG glycome 317 during perimenopause are so extensive, they could potentially be used as a diagnostic tool. 318 In fact, IgG glycome composition could be used to determine long-term average 319 concentrations of sex hormones in the same way glycated hemoglobin (HbA1c) is used to 320 determine long-term concentrations of blood glucose.  $321$  determine long-term concentrations of blood glucose.

321<br>322

322 Iimitations of the study<br>323 The main limitation of this study is relatively long time between individual sampling time 324 points (6.9±2.6 years) that was not tailored for the occurrence of menopause. Therefore, in 325 some cases, perimenopause was just a short part of the period in which the change in the 326 IgG N-glycome occurred, while in others sampling might have occurred within the 327 perimenopause period, with part of the perimenopause being before and another part after 328 a specific sampling. Hopefully, a future study that would have more frequent sampling 329 during the perimenopause period would enable an even more accurate assessment of IgG 330 glycome association with perimenopause. 330 glycome association with perimenopause.

331<br>332

332 Conclusions<br>333 Changes in IgG glycosylation from "young" to "old" glycome associate with many health 334 risks that accompany menopause  $^1$ . In some diseases like rheumatoid arthritis  $^{43,44}$  and 334 - risks that accompany menopause <sup>+</sup>. In some diseases like rheumatoid arthritis <sup>49,44</sup> and<br>335 - cardiovascular diseases <sup>45,46</sup> this change was shown to occur vears before disease onset. 335 trandiovascular diseases <sup>45,46</sup> this change was shown to occur years before disease onset,<br>336 this suggesting the causal role of IgG glycans in disease development. Proinflammatory IgG 337 glycome and the resulting decrease in the ability of IgG to suppress low-grade chronic 338 inflammation may be an important molecular mechanism that mediates the increased 339 health risk in perimenopause, thus this topic should be studied in more detail. 339 health risk in perimenopause, thus this topic should be studied in more detail.

340 Competing interests<br>341 A patent covering all the main aspects of the use of IgG glycome as a predictor of 342 menopause and perimenopause has been filed by Genos Ltd (application number: 343 P20210509A). The application is currently pending. D.K., C.M., and G.L. are named as co-344 inventors on the patent application. G.L. is the founder and owner of Genos Ltd, a biotech 345 company specialising in high-throughput glycomics that also has several patents in the field. 346 H.D., A.Ci. T.P., and I.T.-A. are employees of Genos Ltd. The remaining authors declare no 347 competing interests. 347 competing interests.

### 348

349 Acknowledgements<br>350 This study has been supported by the Croatian National Centre of Excellence in Personalised 351 Healthcare (Contract no. KK.01.1.1.01.0010), ESI Funds grant for the Centre of Competences 352 in Molecular Diagnostics and the Human Glycome Project. Equipment and products from 353 Waters and New England Biolabs were used for this research. The Department of Twin 354 Research receives support from grants from the Wellcome Trust (212904/Z/18/Z) and the 355 Medical Research Council (MRC)/British Heart Foundation (BHF) Ancestry and Biological 356 Informative Markers for Stratification of Hypertension (AIM-HY; MR/M016560/1), European 357 Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd., the NIHR Clinical 358 Research Facility and Biomedical Research Centre (based at Guy's and St Thomas' NHS 359 Foundation Trust in partnership with King's College London). C.M. is funded by the Chronic 360 Disease Research Foundation and by the MRC AIM-HY project grant. 360 Disease Research Foundation and by the MRC AIM-HY project grant.

- 361<br>362
- 





456 the first-line treatment? Post Reprod Heal 2019; 25: 124–30.



478



479 - Supplementary Tables and Figures<br>480 - Supplementary Table 1. Descriptive

## **Supplementary Table 2.** Detailed description of glycan structures according to Keser et al.  $^{23}$ <br>483 corresponding to every individual immunoglobulin RapiFluor-MS glycan peak \*





\*structure abbreviations - all N-glycans have two core N-acetylglucosamines (GlcNAcs); F at 484 \*structure abbreviations – all N-glycans have two core *N*-acetylglucosamines (GlcNAcs); F<br>485 the start of the abbreviation indicates a core-fucose  $\alpha$ 1,6-linked to the inner GlcNAc; Mx,

486 number (x) of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl

487 core; A2, biantennary with both GlcNAcs as  $\beta$ 1, 2-linked; B, bisecting GlcNAc linked  $\beta$ 1, 4 to

488  $\beta$ 1, 3 mannose; G(x), number (x) of  $\beta$ 1, 4 linked galactose on antenna; S(x), number (x) of

489 sialic acids linked to galactose  $\frac{8}{3}$ 

Supplementary Table 3 Formulas used for the calculation of IgG derived traits









**Supplementary Figure 2.** IgG glycome composition in premenopausal and menopausal women, and men. Mean glycan abundances (% of total IgG N-glycome) and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less then 0.1 are shown.



glycan abundances and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less then 0.1 are shown.